Company news: Zelira; ECS Botanics; LGP; Ecofibre; Neurotech; Elixinol; Emyria by Steve Jones and Martin Lane February 28, 2024July 16, 2024 Zelira Therapeutics was hit with a A$30.7m impairment charge in the first half of the financial […]
Emyria S3 CBD trial ‘on hold’ as firm stresses need to focus on revenue by Steve Jones February 7, 2024February 7, 2024
Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024July 11, 2024
Company news: Clever Leaves; Cronos/Vitura; InhaleRX; Emyria; CannMart/Aura Therapeutics; Cann Group; Greenfern Industries; LGP/Reset Mind Sciences by Steve Jones and Martin Lane January 16, 2024July 11, 2024
Company news: Emyria; Wellnex Life; Neurotech International; Melodiol Global Health by Martin Lane November 14, 2023April 30, 2024
Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth by Steve Jones and Martin Lane November 1, 2023November 6, 2023
Company news: Setek Therapeutics; Emyria; Melodiol Global Health by Martin Lane October 9, 2023April 30, 2024
Financial results: Bioxyne/BLS; Emyria; Ecofibre; Zelira Therapeutics by Martin Lane October 3, 2023April 30, 2024
Emyria completes acquisition of Pax Centre for A$1.7m by Martin Lane September 13, 2023April 30, 2024
